Astrivax Therapeutics

Astrivax Therapeutics develops a vaccine technology platform (Launch-iT) to create virus-targeted immunotherapies for virus-driven cancers.

The company is developing Launch-iT, a novel platform to create virus-targeted immunotherapies that address virus-driven cancers and other diseases. Their approach targets viral infections before they cause cancer, opening a new therapeutic space alongside prevention and treatment. The company focuses on conditions like HPV-driven cancer.